Citius Pharmaceuticals, Inc.
CTXR · NASDAQ
9/30/2024 | 9/30/2023 | 9/30/2022 | 9/30/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $210 | $194 | $180 | $165 |
| Gross Profit | -$210 | -$194 | -$180 | -$165 |
| % Margin | – | – | – | – |
| R&D Expenses | $11,907 | $14,820 | $17,655 | $12,241 |
| G&A Expenses | $18,249 | $21,912 | $15,661 | $11,291 |
| SG&A Expenses | $18,249 | $21,912 | $15,661 | $11,291 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $11,840 | $0 | $0 | $0 |
| Operating Expenses | $41,996 | $36,732 | $33,316 | $23,532 |
| Operating Income | -$41,996 | -$36,732 | -$33,316 | -$23,532 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $3,146 | $4,765 | $251 | $477 |
| Pre-Tax Income | -$38,850 | -$31,967 | -$33,065 | -$23,054 |
| Tax Expense | $576 | $576 | $576 | $0 |
| Net Income | -$39,139 | -$32,543 | -$33,641 | -$23,125 |
| % Margin | – | – | – | – |
| EPS | -5.97 | -5.57 | -5.76 | -5.64 |
| % Growth | -7.2% | 3.3% | -2.1% | – |
| EPS Diluted | -5.97 | -5.57 | -5.76 | -5.64 |
| Weighted Avg Shares Out | 11,590 | 9,742 | 9,739 | 7,240 |
| Weighted Avg Shares Out Dil | 11,590 | 10,086 | 9,739 | 7,240 |
| Supplemental Information | – | – | – | – |
| Interest Income | $758 | $1,179 | $251 | $262 |
| Interest Expense | $0 | $0 | $251 | $11 |
| Depreciation & Amortization | $210 | $194 | $180 | $165 |
| EBITDA | -$38,640 | -$31,773 | -$32,885 | -$22,879 |
| % Margin | – | – | – | – |